登录    
  
首页 > 期刊论文 > 论文摘要
CDK12与肿瘤相关性的研究进展
         
Progress in the relevance of CDK12 with tumors

摘    要
恶性肿瘤一般表现为细胞分裂不受控制的病理过程。细胞周期蛋白依赖性激酶 (cyclin-dependent kinases,CDKs)是一类调节细胞周期进程和基因转录过程的关键因子。CDKs的功能失调能够驱动肿瘤的发生,因此常被检测用来指导恶性肿瘤的治疗。CDK12是一种参与包括DNA损伤修复、细胞生长和分化、前体mRNA剪接和处理加工等多种细胞进程的转录相关性激酶。近期研究发现,多种肿瘤中存在着CDK12基因突变和扩增现象,如在高级别浆液性卵巢癌中CDK12基因发生功能缺失性突变,提示CDK12可能是一种抑癌基因。然而,CDK12在某些肿瘤中过表达,表明CDK12还可能具有一些癌基因的特性。本文就CDK12基因的结构、功能以及与恶性肿瘤的关系等最新研究进展进行综述。
标    签 肿瘤   细胞周期蛋白依赖激酶类   DNA修复   细胞周期   CDK12基因   Neoplasms   Cyclin-dependent kinases   DNA repair   Cell cycle   CDK12 gene  
 
Abstract
Cancer represents a pathological characteristic of uncontrolled cell division. The cyclin-dependent kinases (CDKs) are a kinds of key factors regulating cell cycle progression and transcription process. Since the dysregulation of CDKs is a frequently occurring event driving tumorigenesis, CDKs have been tested extensively as the targets for cancer therapy. CDK12 is a transcription-associated kinase which participates in various cellular processes, including DNA damage response, cellular development and differentiation, as well as precursor mRNA splicing and processing. The mutations and amplification of CDK12 gene have been recently reported in different types of malignancies, such as loss-of-function mutations in high-grade serous ovarian carcinomas, which suggests that CDK12 is a tumor suppressor. On the contrary, CDK12 is overexpressed in other tumors, which suggests that CDK12 has some properties of oncogene. This paper reviews the structure and function of CDK12 gene, as well as the relationship between CDK12 gene and cancers.

中图分类号 R730.2   DOI 10.3781/j.issn.1000-7431.2018.55.007

 
  购买该论文  中国光学期刊网论文下载说明
      


所属栏目 综述

基金项目 国家自然科学基金资助项目(编号:81572543)

收稿日期 2018/1/2

修改稿日期 2018/2/6

网络出版日期

作者单位点击查看


引用该论文: WANG Hao,WANG Lili,LI Xin,HOU Dingkun,XU Zihan,DONG Shiqiang,WANG Haitao. Progress in the relevance of CDK12 with tumors[J]. Tumor, 2018, 38(7): 711~715
汪 浩,王丽丽,李 鑫,侯定坤,徐子寒,董世强,王海涛. CDK12与肿瘤相关性的研究进展[J]. 肿瘤, 2018, 38(7): 711~715


论文评价
共有人对该论文发表了看法,其中:
人认为该论文很差
人认为该论文较差
人认为该论文一般
人认为该论文较好
人认为该论文很好
分享论文
分享到新浪微博 分享到腾讯微博 分享到人人网 分享到 Google Reader 分享到百度搜藏分享到Twitter

参考文献
【1】Asghar U, Witkiewicz AK, Turner NC, et al. The history and future of targeting cyclin-dependent kinases in cancer therapy[J]. Nat Rev Drug Discov, 2015, 14(2):130-146.
 
【2】Bruyere C, Meijer L. Targeting cyclin-dependent kinases in anti-neoplastic therapy[J]. Curr Opin Cell Biol, 2013, 25(6):772-779.
 
【3】Chilà R, Guffanti F, Damia G. Role and therapeutic potential of CDK12 in human cancers[J]. Cancer Treat Rev, 2016, 50:83-88.
 
【4】Johnson SF, Cruz C, Greifenberg AK, et al. CDK12 inhibition reverses de novo and acquired PARP inhibitor resistance in BRCA wild-type and mutated models of triple-negative breast cancer[J]. Cell Rep, 2016, 17(9):2367-2381.
 
【5】Zhang T, Kwiatkowski N, Olson CM, et al.Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors[J]. Nat Chem Biol, 2016,12(10):876-884.
 
【6】Ko TK, Kelly E, Pines J. CrkRS: A novel conserved Cdc2-related protein kinase that colocalises with SC35 speckles[J]. J Cell Sci, 2001, 114(14):2591-2603.
 
【7】Chen HH, Wang YC, Fann MJ. Identification and characterization of the CDK12/cyclin L1 complex involved in alternative splicing regulation[J]. Mol Cell Biol, 2006, 26(7):2736-2745.
 
【8】Bartkowiak B, Liu P, Phatnani HP, et al. CDK12 is a transcription elongation-associated CTD kinase, the metazoan ortholog of yeast Ctk1[J]. Genes Dev, 2010, 24(20):2303-2316.
 
【9】Blazek D, Kohoutek J, Bartholomeeusen K, et al. The Cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes[J]. Genes Dev, 2011, 25(20):2158-2172.
 
【10】Cheng SW, Kuzyk MA, Moradian A, et al. Interaction of cyclin-dependent kinase 12/CrkRS with cyclin K1 is required for the phosphorylation of the C-terminal domain of RNA polymeraseⅡ[J]. Mol Cell Biol, 2012, 32(22):4691-4704.
 
【11】B?sken CA, Farnung L, Hintermair C, et al. The structure and substrate specificity of human Cdk12/Cyclin K[J]. Nat Commun, 2014, 5:3505.
 
【12】Liang K, Gao X, Gilmore JM, et al. Characterization of human cyclin-dependent kinase 12 (CDK12) and CDK13 complexes in C-terminal domain phosphorylation, gene transcription, and RNA processing[J]. Mol Cell Biol, 2015, 35(6):928-938.
 
【13】. Li X, Chatterjee N, Spirohn K, et al. Cdk12 is a gene-selective RNA polymeraseⅡ kinase that regulates a subset of the transcriptome, including Nrf2 target genes[J]. Sci Rep, 2016, 6:21455.
 
【14】Yu M, Yang W, Ni T, et al. RNA polymeraseⅡ-associated factor 1 regulates the release and phosphorylation of paused RNA polymeraseⅡ[J]. Science, 2015, 350(6266):1383-1386.
 
【15】Bartkowiak B, Yan C, Greenleaf AL. Engineering an analog-sensitive CDK12 cell line using CRISPR/Cas[J]. Biochim Biophys Acta, 2015, 1849(9):1179-1187.
 
【16】Eifler TT, Shao W, Bartholomeeusen K, et al. Cyclin-dependent kinase 12 increases 3’ end processing of growth factor-induced c-FOS transcripts[J]. Mol Cell Biol, 2015, 35(2):468-478.
 
【17】Tien JF, Mazloomian A, Cheng SG, et al. CDK12 regulates alternative last exon mRNA splicing and promotes breast cancer cell invasion[J]. Nucleic Acids Res, 2017, 45(11):6698- 6716.
 
【18】Ekumi KM, Paculova H, Lenasi T, et al. Ovarian carcinoma CDK12 mutations misregulate expression of DNA repair genes via deficient formation and function of the Cdk12/CycK complex[J]. Nucleic Acids Res, 2015, 43(5):2575-2589.
 
【19】Joshi PM, Sutor SL, Huntoon CJ, et al. Ovarian cancer-associated mutations disable catalytic activity of CDK12, a kinase that promotes homologous recombination repair and resistance to cisplatin and poly(ADP-ribose) polymerase inhibitors[J]. J Biol Chem, 2014, 289(13):9247-9253.
 
【20】Paculova H, Kramara J, Simeckova S, et al. BRCA1 or CDK12 loss sensitizes cells to CHK1 inhibitors[J]. Tumour Biol, 2017, 39(10):1010428317727479.
 
【21】Lord CJ, Ashworth A. The DNA damage response and cancer therapy[J]. Nature, 2012, 481(7381):287-294.
 
【22】Bell D, Berchuck A, Birrer M, et al. Integrated genomic analyses of ovarian carcinoma[J]. Nature, 2011, 474(7353):609-615.
 
【23】Bajrami I, Frankum JR, Konde A, et al. Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity[J]. Cancer Res, 2014, 74(1):287-297.
 
【24】Carter SL, Cibulskis K, Helman E, et al. Absolute quantification of somatic DNA alterations in human cancer[J]. Nat Biotechnol, 2012, 30(5):413-421.
 
【25】Koboldt DC, Fulton RS, McLellan MD, et al. Comprehensive molecular portraits of human breast tumours[J]. Nature, 2012, 490(7418):61-70.
 
【26】Shah SP, Roth A, Goya R, et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers[J]. Nature, 2012, 486(7403):395-399.
 
【27】Iorns E, Martens-de Kemp SR, Lord CJ, et al. CRK7 modifies the MAPK pathway and influences the response to endocrine therapy[J]. Carcinogenesis, 2009, 30(10):1696-1701.
 
【28】Mertins P, Mani DR, Ruggles KV, et al. Proteogenomics connects somatic mutations to signalling in breast cancer[J]. Nature, 2016, 534(7605):55-62.
 
【29】Naidoo K, Wai PT, Maguire SL, et al. Evaluation of CDK12 protein expression as a potential novel biomarker for DNA damage response targeted therapies in breast cancer[J]. Mol Cancer Ther, 2017, 17(1):306-315.
 
【30】Johannes J, Denz CR, Su N, et al. Structure based design of selective non-covalent CDK12 inhibitors[J]. ChemMedChem, 2018, 13(3):231-235.
 
【31】Parry D, Guzi T, Shanahan F, et al. Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor[J]. Mol Cancer Ther, 2010, 9(8):2344-2353.
 
【32】Lim E, Johnson SF, Geyer M, et al. Sensitizing HR-proficient cancers to PARP inhibitors[J]. Mol Cell Oncol, 2017, 4(6):1-3.
 
【33】Capra M, Nuciforo PG, Confalonieri S, et al. Frequent alterations in the expression of serine/threonine kinases in human cancers[J]. Cancer Res, 2006, 66(16):8147-8154.
 
相关信息
   标题 相关频次
 PALB2在去势抵抗性前列腺癌中的表达及意义
 12
 去势抵抗性前列腺癌新型内分泌药物治疗次序的研究进展
 8
 晚期BRAFV600E突变直肠癌1例循证治疗
 8
 沉默PIK3C2B基因的表达可抑制前列腺癌PC-3细胞的增殖及侵袭
 4
 核干细胞因子与肿瘤的研究进展
 4
 碱基切除修复与抗肿瘤药物耐药
 4
 联合放/化疗对细胞周期特异性凋亡的影响
 4
 人骨髓间充质干细胞条件培养液对前列腺癌PC-3细胞生长的影响
 4
 细胞周期调控因子CDC25A及其抑制剂在肿瘤治疗中的研究进展
 4
 新藤黄酸诱导人结肠癌HCT116细胞凋亡的作用机制研究
 4
 肿瘤干细胞与放疗抵抗的研究进展
 4
 CDK抑制剂BMS-265246体外诱导肝癌细胞周期阻滞和细胞凋亡
 3
 体外Fas介导肿瘤细胞凋亡过程中cyclins/CDKs的变化规律及调节机制
 3
 BRAFV600E突变基因沉默可抑制甲状腺乳头状癌细胞增殖
 2
 CRISPR/Cas9基因编辑技术在肿瘤研究及治疗中的应用
 2
 DACH1基因对人子宫内膜癌HEC-1A细胞增殖的影响
 2
 EIF5A2基因在恶性肿瘤中的研究进展
 2
 MS4A基因家族与肿瘤的研究进展
 2
 SEPT 9基因与恶性肿瘤关系的研究进展
 2
 125I内放疗联合热疗和化疗治疗中晚期肿瘤的临床观察
 2
 18F-FDG PET/CT在同时性多原发癌中的应用
 2
 1-磷酸鞘氨醇对恶性肿瘤生物学行为调控的研究进展
 2
 3株肺癌细胞中9个肿瘤相关基因的启动子甲基化状态和部分基因表达的相关性(英文)
 2
 9-顺式维甲酸对胃癌细胞周期及周期因子表达的影响
 2
 AMPK在肿瘤发生发展中的作用机制研究
 2
 Arresten抑制HUVEC细胞增殖和管腔形成的实验研究
 2
 ATRA诱导结肠癌细胞株LoVo分化与凋亡
 2
 Bcl-2与IP3R相互作用调控肿瘤细胞程序性死亡的研究进展
 2
 Camptothecin(CPT)和Cytosine arabinoside(Ara-C)联合应用对MOLT-4细胞株周期特异性凋亡的影响
 2
 CCAAT/增强子结合蛋白α对K562细胞分化和凋亡的影响及其机制
 2

  热点专题


关于我们  |   联系我们  |   广告投放  |   《肿瘤》杂志社版权所有 《肿瘤》杂志社   © 中国 上海 2014.3
沪ICP备15036656号-2